We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Low-Cost Portable Screening Test to Transform Kidney Disease Detection

By LabMedica International staff writers
Posted on 17 Apr 2025

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. More...

This silent epidemic not only diminishes the quality of life for those affected but also imposes significant financial strain on healthcare systems due to the costs associated with dialysis and organ transplants. However, early diagnosis can significantly alter a patient’s course of treatment, offering better options and potentially halting or slowing the progression of the disease. The challenge lies in the fact that current kidney function tests typically require visits to a laboratory, expensive equipment, skilled personnel, and several days to obtain results. These requirements make routine screenings difficult, particularly for those in rural and Indigenous communities. Now, researchers have created an innovative tool that could revolutionize how kidney disease is diagnosed, especially in underserved areas.

A team of researchers from the University of Manitoba (Winnipeg, Canada) has developed a device known as the uCR-Chip, a low-cost, portable diagnostic tool designed to make kidney function testing faster, more convenient, and widely accessible. The results are available in less than seven minutes, and the test does not require specialized laboratory equipment. Their research, published in Microsystems & Nanoengineering, showcases how this device could play a crucial role in enhancing early detection and improving outcomes for individuals living with chronic kidney disease (CKD). The uCR-Chip addresses the challenges of current testing methods by utilizing a color-based chemical reaction to measure creatinine, a key biomarker of kidney health, from a small urine sample. Since it does not require advanced lab equipment, it can be used directly in health clinics or mobile healthcare settings.

The uCR-Chip has the potential to relieve pressure on healthcare systems by identifying kidney issues at earlier stages, thereby reducing the number of patients who progress to more advanced stages of disease. This could lead to fewer patients requiring costly treatments such as dialysis or transplants, allowing for more effective management with early interventions. In many rural, remote, and Indigenous communities, where access to advanced diagnostic equipment is limited, the uCR-Chip offers a portable, cost-effective alternative that could greatly improve access to vital testing. As healthcare systems worldwide seek affordable solutions to manage chronic diseases, innovations like the uCR-Chip offer not just hope, but tangible solutions that bring life-saving diagnostics to those who need them most.

“Traditional lab test can take days and may delay diagnosis,” said Dr. Francis Lin who led the research team. “Our new test method will lead to faster, more accessible and reliable diagnostic results to prevent irreversible kidney damage.”

Related Links:
University of Manitoba


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Vasculitis Diagnostic Test
AESKULISA Vasculitis-Screen
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.